Reactive microgliosis engages distinct responses by microglial subpopulations after minor central nervous system

Martin Wirenfeldt1, Alicia Anne Babcock, Rune Ladeby

  • 1Medical Biotechnology Center, University of Southern Denmark, Odense. mwnielsen@health.sdu.dk

Insights

In CNS injury, both resident and immigrant microglia respond. Distinct microglial subpopulations show varied responses to central nervous system (CNS) damage, impacting repair and therapy.

Area of Science:

  • Neuroscience
  • Immunology
  • Cell Biology

Background:

  • Microglia are the primary immune cells of the central nervous system (CNS).
  • Reactive microgliosis, the microglial response to CNS injury, involves both resident and immigrant cells.
  • The cellular dynamics and heterogeneity of reactive microglia remain incompletely understood.

Purpose of the Study:

  • To investigate the cellular composition and kinetics of reactive microglia following CNS injury.
  • To differentiate between resident and immigrant microglia and characterize their activation states.
  • To explore the heterogeneity of microglial responses to axonal degeneration.

Main Methods:

  • Utilized bone marrow chimeric mice reconstituted with green fluorescent protein (GFP)-expressing donor cells.
  • Induced entorhinal cortex lesions to model CNS injury and axonal degeneration.
  • Employed flow cytometry on dissected hippocampi to analyze microglial populations (CD11b, CD45, CD34 markers).

Main Results:

  • Identified distinct subpopulations of resident (GFP-) and immigrant (GFP+) microglia.
  • Immigrant microglia increased significantly post-lesion, reaching 13% by 7 days.
  • A subset of resident microglia transiently expressed CD34, indicating a specific activation state.

Conclusions:

  • CNS injury elicits heterogeneous microglial responses involving distinct resident and immigrant cell populations.
  • The observed heterogeneity in microglial subpopulations may influence CNS repair mechanisms.
  • Understanding microglial heterogeneity is crucial for developing effective CNS therapies.